企業の回答
Novo Nordisk statement
We support a mandatory reporting mechanism for European companies that manufacture or contract to manufacture products containing 3TG necessary to product functionality or manufacture. The reporting mechanism should mirror the US Securities and Exchange Commission requirements to ensure a consistent international framework.